Archive for 2013

Honouring Former President Nelson Mandela

Johannesburg, Friday 6 December 2013 – Today, as the world mourns the passing of one of its most outstanding citizens and South Africa’s former President, Nelson Rolihlahla Mandela, Aspen, joins the millions of people worldwide, in expressing its deepest condolences to the family and friends of this humble leader. Stephen Saad, Aspen Group Chief Executive…

Read More

Aspen concludes the acquisition of an API Business from MSD

01 October 2013 By : Shauneen Beukes 1 October 2013 Oss, the Netherlands – JSE Limited listed Aspen Holdings, the ninth largest generic pharmaceutical company in the world, has announced that the Aspen Group (“Aspen”), has finalised the acquisition of Active Pharmaceutical Ingredient (API) manufacturing operations and related businesses (“the API Business”) from MSD, known…

Read More

Aspen acquires GSK brands and manufacturing site for £700 million

Durban, South Africa: Aspen Global Incorporated (“AGI”), a wholly owned subsidiary of Aspen, announced today that it will acquire from GlaxoSmithKline plc (“GSK”) the Arixtra and Fraxiparine/Fraxodi brands (“the Brands”) and business worldwide, except in China, Pakistan and India (“the Excluded Territories”) as well as a specialised sterile production site which manufactures the Brands at…

Read More

Aspen’s revenue soars to R19.3 billion

Johannesburg – JSE Limited listed Aspen Pharmacare Holdings Limited (APN), the ninth largest generic company in the world and Africa’s largest pharmaceutical manufacturer, has announced excellent results for the year ended 30 June 2013. Group Performance Revenue from continuing operations increased by 27% to R19.3 billion. Operating profit from continuing operations rose by 28% to…

Read More

R5 million injection for Nelson Mandela Children’s hospital

Johannesburg: Aspen Pharmacare, a JSE-listed leading pharmaceutical company in the southern hemisphere, provided a financial injection towards the establishment of the Nelson Mandela Children’s Hospital at the inaugural Mandela Sports and Culture Day. Stephen Saad, Aspen Group Chief Executive together with the Minister of Health, Dr Aaron Motsoaledi last year raised R10 million through the…

Read More

Aspen signs R10 billion deal with MSD

Oss, Netherlands – JSE Limited listed Aspen Holdings is pleased to announce that the Aspen Group (“Aspen”), the ninth largest generic pharmaceutical company in the world, has: signed an agreement with MSD (known as Merck in the United States and Canada) for the acquisition of an active pharmaceutical ingredient (“API”) manufacturing business which manufactures for…

Read More

Renewal of Cautionary Announcement

APN – Aspen Pharmacare Holdings Limited – Trading statement Aspen Pharmacare Holdings Limited (Incorporated in the Republic of South Africa) (Registration number 1985/002935/06) Share code: APN & ISIN: ZAE000066692 (“Aspen”) Renewal of Cautionary Announcement Shareholders are referred to the renewal cautionary announcement released by Aspen on 7 March 2013 in which shareholders were advised of…

Read More

Aspen to invest more than R1,9 billion in infant nutritional deal with Pfizer

Shareholders of Aspen Holdings are advised that Aspen Group companies (“Aspen”) have concluded agreements with Nestlé S.A. in respect of the acquisition of certain rights to intellectual property licenses, net assets and shares in the IN businesses presently conducted by Pfizer which distribute a portfolio of IN products in Australia (the “Australian IN business”) and…

Read More

Aspen increases revenue to R9 billion

JSE Limited listed Aspen Pharmacare Holdings Limited (Apn), the ninth largest generic company in the world and Africa’s largest pharmaceutical manufacturer, has announced excellent results for the interim period ended 31 December 2012. Group Performance Revenue from continuing operations increased by 20% to R9.0 billion. Operating profit from continuing operations rose by 24% to R2.5…

Read More

Renewal of Cautionary Announcement

Shareholders are referred to the cautionary announcement released by Aspen on 4 February 2013 (and subsequent renewals of this cautionary announcement) in which shareholders were advised of discussions between Aspen and MSD, known as Merck in the United States and Canada, in respect of a possible transaction comprising the acquisition of an active pharmaceutical ingredient…

Read More